August 2025 - Cambridge Cognition

Cambridge Cognition Investment, Monument Therapeutics, Announces Partnership with Foundation for the National Institutes of Health for Clinical Trial of MT1988, a Novel Treatment for Schizophrenia

19 August 2025 / News

Cambridge Cognition Investment, Monument Therapeutics, Announces Partnership with Foundation for the National Institutes of Health for Clinical Trial of MT1988, a Novel Treatment for Schizophrenia 19 August 2025 Cambridge UK, August 19, 2025 – Cambridge Cognition (AIM: COG), the brain health software group specialising in digital health products that advance brain health research and treatment, is […]

Cognition in The Blood (Biomarker)

18 August 2025 / Events, Insights, Publications & posters

Cognition in The Blood (Biomarker) How do digital cognitive assessments relate to the Blood Plasma p-Tau217 in patients with Mild Cognitive Impairment (MCI)? Our latest research explores an exciting dataset with the AI–Mind Project, who have given us the opportunity to test the associations of our cognitive assessments alongside classic paper-and-pencil tests to levels of

Cognition in The Blood (Biomarker) Read More »

Cambridge Cognition launches Speaker Identification Solution to Safeguard Clinical Trial Integrity

12 August 2025 / News

Cambridge Cognition launches Speaker Identification Solution to Safeguard Clinical Trial Integrity 12 August 2025 Cambridge Cognition Holdings plc (AIM:COG), the brain health software group specialising in digital health products that advance brain health research and treatment, is pleased to announce the commercial launch of a proprietary speaker identification solution developed to tackle duplicate participant enrolment

Cambridge Cognition launches Speaker Identification Solution to Safeguard Clinical Trial Integrity Read More »